Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) PT at $127.44

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been assigned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $126.00.

Several analysts have recently issued reports on the stock. Morgan Stanley decreased their target price on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th.

BioNTech Trading Up 0.3%

Shares of BNTX opened at $96.73 on Tuesday. The stock has a market capitalization of $24.46 billion, a PE ratio of -12.35 and a beta of 1.29. The company’s fifty day moving average is $96.98 and its 200 day moving average is $95.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter last year, the business earned ($1.60) EPS. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. Sell-side analysts expect that BioNTech will post -6.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ugur Sahin sold 20,500 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00. Following the sale, the chief executive officer owned 688,209 shares in the company, valued at approximately $66,281,408.79. This represents a 2.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 170,000 shares of company stock worth $17,053,965. Corporate insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Engineers Gate Manager LP raised its stake in shares of BioNTech by 17.3% in the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech during the 2nd quarter worth about $39,000. Nykredit A S purchased a new position in shares of BioNTech during the 2nd quarter worth about $293,000. B. Metzler seel. Sohn & Co. AG grew its holdings in BioNTech by 66.7% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after purchasing an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in BioNTech during the 2nd quarter valued at about $2,520,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.